MYB and acute myeloid leukemia: In our analytical results, low expression of MYB in early differentiation-responsive MEP subtypes (stage 3) aligns with its inhibitory potential in normal erythropoiesis, while its upregulation in both mRNA and protein levels in AML samples indicates a dysregulated regulatory shift.